• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pixie Dust Technologies, Inc. Announces Fiscal Year 2023 Financial Results

    11/17/23 8:30:00 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PXDT alert in real time by email

    NEW YORK and TOKYO, Nov. 17, 2023 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, today announced its financial results for the fiscal year ended April 30, 2023.

    Pixie Dust Technologies Logo (CNW Group/Pixie Dust Technologies)

    Recent Operational Highlights

    • Held a Bell Ringing Ceremony on August 25, 2023 at the Nasdaq MarketSite Tower in New York City to commemorate the Company's recent IPO.
    • Announced the development of an acoustic metamaterial sound insulation product that allows air to pass while blocking out sound. The application can be used in various fields such as air conditioning, building materials, furniture and fixtures, railways, construction work, and automobiles.
    • Launched the public sales of the following products:
      • SonoRepro, an at-home scalp care device that uses ultrasonic waves to stimulate the scalp. SonoRepro was jointly developed by the Company and Angfa Co., Ltd.
      • kikippa, an acoustic stimulation device functioning as a speaker that utilizes our technology to implement period-equivalent amplitude modulation to daily speech, such as television or radio broadcasts. kikippa was jointly developed by the Company and Shionogi & Co., Ltd.
      • VUEVO, a series of products which can display the direction and content of a speaker's speech by using a wireless microphone and dedicated software application for real-time conversation visualization.

    Fiscal Year Financial Results

    The Company's audited financial statements for the fiscal year ended April 30, 2023 and the related notes, and related management's discussion and analysis of the Company's financial condition and results of operations can be found in the Company's Annual Report on Form 20-F filed with the SEC, a copy of which can also be found on the Company's website. The Company's functional currency and reporting currency is the Japanese yen (which we refer to as "JPY" or "¥"). The terms "dollar," "USD," "US$" or "$" refer to U.S. dollars, the legal currency of the United States. Convenience translations included in this annual report of Japanese yen into U.S. dollars have been made at the exchange rate of ¥135.99 = US$1.00, which was the foreign exchange rate on April 28, 2023 as reported by the Board of Governors of the Federal Reserve System. All figures are expressed in Japanese Yen and United States dollars unless otherwise stated.

    • Total Revenue increased by 10.8% from approximately ¥636.3 million in the fiscal year ended April 30, 2022 to approximately ¥704.7 million ($5.2 million) in the fiscal year ended April 30, 2023, primarily due to increases in product revenue of ¥182.9 million, partially offset by a decrease in commissioned research and development of ¥67.2 million and a decrease in revenue from solution service.
    • Product Sales were approximately ¥182.9 million ($1.3 million) in the fiscal year ended April 30, 2023, representing a 100% increase from the prior year. The increase was primarily attributable to the sales of SonoRepro, which was launched in November 2022, and to a lesser degree, sales of iwasemi, which was launched in July 2022.
    • Services Sales declined to ¥521.8 million ($3.8 million) in the fiscal year ended April 30, 2023 from ¥636.3 million ($4.7 million) in the prior year. The decline was primarily due to lower demand for COVID-19 related magickiri service which analyzed the movement of air and people in a room and provided advice on ventilation for commercial customers. Since April 2023, there have been no outstanding contracts for magickiri, and the Company no longer generates revenue from this service.
    • Research and Development Expenses remained relatively flat for the year ended April 30, 2023 compared to the prior year and is primarily affected by selection and concentration of development products.
    • Selling, General and Administrative Expenses increased to ¥1.9 billion ($13.6 million) in the fiscal year ended April 30, 2023 from ¥833.0 million ($6.1 million) in the prior year, due to increases in advertising expenses related to new products and marketing fees, and fees and expenses associated with the Company's recent IPO and Nasdaq listing.
    • Other Income increased to ¥43.8 million ($322,000) in the fiscal year ended April 30, 2023 from ¥13.0 million ($96,000) in the prior year, primarily due to the receipt of insurance proceeds in 2023 related to a claim for losses that occurred in the year ended April 30, 2022, partially offset by a decrease in subsidy income.
    • Net Loss was ¥2.0 billion ($14.5 million) in the fiscal year ended April 30, 2023 compared to ¥1.1 billion ($8.2 million) in the prior year.
    • As of April 30, 2023, the Company had ¥2.1 billion ($15.7 million) in cash and cash equivalents compared to ¥1.8 billion ($13.2 million) as of April 30, 2022, which were held and used for working capital purposes. The Company's cash and cash equivalents generally consist of cash on hand, demand deposits, and time deposits maintained at various financial institutions.

    Forward-Looking Statements

    Certain statements contained in this press release are "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including the strength of the economy, changes to the market for securities, political or financial instability and other factors which are set forth in the Company's Annual Report on Form 20-F for the year ended April 30, 2023 filed with the SEC (File No. 001-41749), and in all filings with the SEC made by the Company subsequent to the filing thereof. The Company does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

    About Pixie Dust Technologies, Inc.

    Pixie Dust Technologies, Inc. is a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is currently focusing on two areas of product development: (1) "Personal Care & Diversity", where wave control technology is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) "Workspace & Digital Transformation," where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems, such as in offices or construction sites, are applied.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pixie-dust-technologies-inc-announces-fiscal-year-2023-financial-results-301991558.html

    SOURCE Pixie Dust Technologies

    Get the next $PXDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PXDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • /C O R R E C T I O N -- Pixie Dust Technologies/

      This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release. (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission. NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Te

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

      NEW YORK and TOKYO, Oct. 23, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows: 1.                  Reasons for Applying for Delisting The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets an

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Financials

    Live finance-specific insights

    See more
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024

      NEW YORK and TOKYO, Feb. 11, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Monday, February 12, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/11/24 12:48:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024

      NEW YORK and TOKYO, Feb. 6, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Tuesday, February 13, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/6/24 9:00:00 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:11:11 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:08:59 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:06:35 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Pixie Dust Technologies Announces CFO Transition

      NEW YORK and TOKYO, March 13, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, announced the appointment of Nobuhiro Takagi and Nobufusa Tarumi as co-Chief Financial Officer ("co-CFO"), effective March 13, 2024. Messrs. Takagi and Tarumi succeed Mr. Mamoru Miwa, whose resignation was not the result of any disagreement or conflict with the Company, its operations, policies, or practices. The role of the Company's Chief Accounting Officer ("CAO"), previously held by Nobuhiro Takagi, will be assumed by the co-CFOs.

      3/13/24 4:05:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    SEC Filings

    See more
    • SEC Form 6-K filed by Pixie Dust Technologies Inc.

      6-K - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/25/24 8:00:20 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Pixie Dust Technologies Inc.

      25 - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/4/24 4:30:02 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.

      6-K/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      10/24/24 1:55:49 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care